GSK goes to China for $1B siRNA deal in Arrowhead’s obesity lanenews2026-05-06T13:39:55+00:00May 6th, 2026|Endpoints News|
Bayer to buy Perfuse Therapeutics for $300M upfrontnews2026-05-06T10:56:39+00:00May 6th, 2026|Endpoints News|
Pfizer’s Albert Bourla says he has no mega-merger plansnews2026-05-05T18:16:42+00:00May 5th, 2026|Endpoints News|
Madrigal extends MASH deal streak with Arrowhead drug that J&J didn’t wantnews2026-05-05T13:25:50+00:00May 5th, 2026|Endpoints News|
UCB bets $2 billion on Candid’s T cell engager ambitionsnews2026-05-04T01:54:30+00:00May 4th, 2026|Endpoints News|
Acelyrin founder Shao-Lee Lin emerges at Cue, as it becomes latest to license from Chinanews2026-05-01T15:27:46+00:00May 1st, 2026|Endpoints News|
Save the date: Premium subscriber-exclusive Post-Hoc Livenews2026-05-01T15:23:08+00:00May 1st, 2026|Endpoints News|
After Apellis deal, Biogen looks to fill early-stage pipelinenews2026-04-29T15:15:09+00:00April 29th, 2026|Endpoints News|
Chiesi signs $1.9B deal to acquire KalVista and its approved drugnews2026-04-29T13:25:38+00:00April 29th, 2026|Endpoints News|
MPM has collected three China drugs for its ‘best of both worlds’ strategynews2026-04-29T11:00:19+00:00April 29th, 2026|Endpoints News|
